Antiinfectives | German Center for Infection Research

Short description

Antiinfectives are medicine to treat infectious diseases.

Detailed description

They can be effective against bacteria, fungi, viruses, and protozoans. The DZIF emphasized the special role of antibiotics among the antiinfectives by renaming the Research Area “Novel Antiinfectives” into “Novel Antibiotics” in 2016.

Postdoctoral Research

Bonn - Köln

Junior Research Group Leader in Pathogenic Ecophysiology (m/f/d) Institute of Pharmaceutical Microbiology

Electron micrograph of a cluster of yellow-stained round bacteria

New agent inhibits Staphylococcus aureus toxin: hope for pneumonia patients

An international research group led by scientists of the German Center for Infection Research (DZIF) at the Helmholtz Centre for Infection Research (HZI) has discovered a promising new drug candidate

University of Tübingen

PAFAP—Pseudomonas aeruginosa-focused anti-infectives pipeline

In the current WHO list of bacterial priority pathogens (WHO BPPL 2024), the World Health Organisation classifies carbapenem-resistant Pseudomonas aeruginosa bacteria as a high-priority pathogen, which means there is an urgent need for new anti-infectives to combat this problematic bacterium. To ...

Scientists sound the alarm over lack of antibiotics

According to the WHO, antimicrobial resistance (AMR) is one of the ten greatest threats to global health. In the EU alone, around 35,000 people die every year from antibiotic-resistant infections. The

Developing novel strategies against tuberculosis and malaria

Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders

BioVersys AG and Helmholtz Centre for Infection Research join forces to accelerate AMR research and development

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug

Schematic structure of BTZ-043 with three six-membered rings and side chains.

Leibniz active agent of the year 2023 is a tuberculosis antibiotic candidate

The drug candidate BTZ-043 has a novel mechanism of action and belongs to a new class of substances. Discovered at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI

Bridging Topic: Microbiome

Trillions of microorganisms colonise the intestine and other surfaces of the human body—this with its incredible diversity is vital for humans. At the same time, if it gets out of balance

Bridging Topic: Antibody-Based Therapies

Monoclonal have great potential to be used effectively to protect against and treat infectious diseases. Their development into new drugs is more necessary than ever at a time when

Bridging Topics

Current developments in infection research challenge the scientific community: Many problems can only be solved if expertise from different disciplines comes together. To meet this challenge, the DZIF